We surmise that such TSPY antibodies could mediate various humoral immune responses [53, 54], including activating the complement system and antibody-dependent cell-mediated cytotoxicity (ADCC), thereby eliminating TSPY-positive tumor cells in the host. Here, TSPY1 is linked to neoplasm.